Hematology · USMLE Step 1 and Step 2

GPIIb-IIIa Inhibitors song

GPIIb-IIIa Inhibitors - Mechanism & Uses, as a song. Hear the short teaser here. The full song is on YouTube and Spotify.

GPIIb-IIIa Inhibitors

Full song on YouTube ↗Spotify ↗

Key points in this song10

GPIIb/IIIa inhibitors block the final common pathway of platelet aggregation by preventing fibrinogen and von Willebrand factor from cross-linking activated platelets.
The three main agents are abciximab (monoclonal antibody), eptifibatide (cyclic peptide), and tirofiban (small molecule peptidomimetic).
Primary indication is acute coronary syndrome (NSTEMI/UA) and percutaneous coronary intervention (PCI) to reduce ischemic complications.
Abciximab has the longest receptor binding duration (days) due to its high affinity for GPIIb/IIIa, while eptifibatide and tirofiban have shorter half-lives (hours).
Major adverse effect is bleeding; the most feared complication is intracranial hemorrhage, and all agents are contraindicated in active bleeding or recent stroke.
Thrombocytopenia is a class effect; abciximab carries the highest risk of acute profound thrombocytopenia, which can occur within hours of administration.
Eptifibatide and tirofiban are renally cleared and require dose adjustment in renal insufficiency; abciximab does not require renal dosing adjustment.
GPIIb/IIIa inhibitors are used alongside aspirin and heparin (or UFH) in high-risk ACS patients undergoing PCI, representing triple antiplatelet/anticoagulant strategy.
Unlike ADP receptor antagonists (clopidogrel), GPIIb/IIIa inhibitors act downstream of all platelet activation pathways, making them the most potent antiplatelet agents available.
Platelet transfusion can partially reverse abciximab's effects (since it redistributes to new platelets), but is ineffective for eptifibatide and tirofiban due to their small-molecule competitive nature.